280 related articles for article (PubMed ID: 35474582)
21. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
22. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
Hesse L; Petersen AH; Nawijn MC
Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
[TBL] [Abstract][Full Text] [Related]
23. Allergen Stability and Immunological Reactivity during Co-dissolution and Incubation of House Dust Mite and Japanese Cedar Pollen SLIT-Tablets.
Watanabe A; Yamamoto T; Matsuhara H; Matsui H; Nakazawa H; Lund K; Ohashi-Doi K
Biol Pharm Bull; 2020 Oct; 43(10):1448-1450. PubMed ID: 32759600
[TBL] [Abstract][Full Text] [Related]
24. Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA.
Muddaluru V; Valenta R; Vrtala S; Schlederer T; Hindley J; Hickey P; Larché M; Tonti E
Allergy; 2021 Jul; 76(7):2177-2188. PubMed ID: 33484161
[TBL] [Abstract][Full Text] [Related]
25. Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan.
Okamoto Y; Kato M; Ishii K; Sato Y; Hata T; Asaka Y
Immunotherapy; 2023 Nov; 15(16):1401-1414. PubMed ID: 37727966
[TBL] [Abstract][Full Text] [Related]
26. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens.
Huang HJ; Curin M; Banerjee S; Chen KW; Garmatiuk T; Resch-Marat Y; Carvalho-Queiroz C; Blatt K; Gafvelin G; Grönlund H; Valent P; Campana R; Focke-Tejkl M; Valenta R; Vrtala S
Allergy; 2019 Dec; 74(12):2461-2478. PubMed ID: 31228873
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
28. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of molecular profiling of allergen-antibody responses in HDM-immunotherapy patients.
Nittner-Marszalska M; Kopeć A; Foks-Ciekalska A; Lata A; Bogacz-Piaseczyńska A; Rosiek-Biegus M; Zajac M; Bożek A
Hum Vaccin Immunother; 2022 Dec; 18(7):2148815. PubMed ID: 36444880
[TBL] [Abstract][Full Text] [Related]
30. Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4.
Feng M; Luo T; Xian M; Shi X; Qin R; Zeng X; Su Q; Li J
Clin Exp Allergy; 2022 Jul; 52(7):878-887. PubMed ID: 34962673
[TBL] [Abstract][Full Text] [Related]
31. Evaluation and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens using a new multiplex assay: a real-life experience on an Italian population.
Villalta D; Scala E; Asero R; Da Re M; Conte M; Buzzulini F
Eur Ann Allergy Clin Immunol; 2022 May; 54(3):117-122. PubMed ID: 33728837
[No Abstract] [Full Text] [Related]
32. Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma.
Hoof I; Bønnelykke K; Stranzl T; Brand S; Li X; Shamji MH; Meyers DA; Bateman ED; Bleecker E; Andersen PS
Thorax; 2024 Mar; 79(4):332-339. PubMed ID: 38160049
[TBL] [Abstract][Full Text] [Related]
33. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
34. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy.
Batard T; Baron-Bodo V; Martelet A; Le Mignon M; Lemoine P; Jain K; Mariano S; Horiot S; Chabre H; Harwanegg C; Marquette CA; Corgier BP; Soh WT; Satitsuksanoa P; Jacquet A; Chew FT; Nony E; Moingeon P
Allergy; 2016 Feb; 71(2):220-9. PubMed ID: 26485347
[TBL] [Abstract][Full Text] [Related]
35. [Profiles of IgE sensitization to dust mite allergen components in patients with allergic rhinitis and asthma].
Wang X; Pu X; Chen L; Guo M; Zheng C; Wang H; Wang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Aug; 36(8):576-581. PubMed ID: 35959573
[No Abstract] [Full Text] [Related]
36. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
37. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
[TBL] [Abstract][Full Text] [Related]
38. Real-Life Study for the Diagnosis of House Dust Mite Allergy - The Value of Recombinant Allergen-Based IgE Serology.
Becker S; Schlederer T; Kramer MF; Haack M; Vrtala S; Resch Y; Lupinek C; Valenta R; Gröger M
Int Arch Allergy Immunol; 2016; 170(2):132-7. PubMed ID: 27505432
[TBL] [Abstract][Full Text] [Related]
39. Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE cross-reactivity.
Curin M; Garmatiuk T; Resch-Marat Y; Chen KW; Hofer G; Fauland K; Keller W; Hemmer W; Vrtala S; Focke-Tejkl M; Valenta R
Allergy; 2018 Aug; 73(8):1653-1661. PubMed ID: 29319884
[TBL] [Abstract][Full Text] [Related]
40. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
